Outcome Capital - Strategic Life Sciences Investment Banking

Creating outcomes like no other. Maximizing your company’s value…

Unique Insights

In-Depth Industry Experience & Networks

Personal Commitment to Clients

Exceptional Record of Success

Community

About Outcome Life Sciences Pulse

Outcome Capital as one of the Top 10 Life Science Financial Service Providers 2023

July 20, 2022

Read More
Driven to create value for our clients to secure the best possible outcome

The added value Outcome Capital was responsible for was 10 times greater than the value we invested in their services. Our only regret was in not bringing them on sooner.

John D Green, MD CEO, Advanced Uro-Solutions
An Outcome professional served as lead banker in the sale of Annese & Associates. His knowledge of our industry, extensive contacts within it, and attention to all facets of the transaction proved invaluable. His care and commitment to the Annese shareholders, board, myself and by extension to all of our employees was simply outstanding.

Ray Apy CEO, Annese & Associates
The diversity of backgrounds enables Outcome to offer deep understanding and unique insights

The Outcome team got fully up to speed with all aspects of our technology and business, and could pitch our company’s story, and value proposition, as well as anyone. They researched a full list of potential acquirers in order to target those with high potential, and articulate the true value proposition for each target in very clear terms.

Victor Esch, PhD President & CEO, DNAe
Outcome Capital’s knowledge and expertise were crucial in bringing this transaction to fruition. Outcome advised us on both the acquisition and the financing and exceeded all our expectations.

Rolf Purzer CEO, ATPCO
A true partner and collaborator

Outcome Capital was a true partner and collaborator starting from the evaluation and sourcing phase. Their teamwork and attention to detail was perfectly accompanied by their knowledge and expertise with the industry segment. Furthermore, their diligence prep rigor was extremely useful once we got to the post term-sheet/closing phase of the transaction. I could not have survived this transaction without their help.

Rohit Nayak CEO, Electronic Registry Systems
In-depth industry knowledge & networks

I was impressed by Outcome Capital’s thoughtful M&A strategy and process, which stemmed from their ability to capture the complexities of Beryllium’s scientific and business value propositions.

Johan Pontin CEO, Beryllium Discovery
The Outcome Capital team was a committed and flexible partner that proved critical to a successful acquisition.

Mahfuz Ahmed CEO, DISYS
Passionately working for our clients' success

I have worked with Outcome Capital on multiple, complex transactions. They bring strategic insights and operational experience to the table like no other investment bankers I have ever worked with.

Lisa Dunlea CEO, XableCath
I knew Outcome by reputation, and they were the only group I felt comfortable engaging with and trusting with this deal. What they provided exceeded my expectations not only in value, but also in their conduct and earnestness. It was a pleasure doing business with Outcome Capital.

Andrew Ferrara Chairman, Boston Healthcare Associates
I thank the Outcome team for driving the Verrix acquisition to completion, for protecting our interests and for an excellent job in navigating the bumps along the way. The Outcome team ran a solid competitive process that caused the market to speak toward a transaction for the benefit of both buyer and seller.

Sami El-Saden Chairman and CEO, Verrix
We cannot thank you enough. We appreciate your guidance, expertise, candor, and the fact that you really care. What a great way to do business.

William Peterson Founder & Director, Propella Therapeutics

Transactions

Has been acquired by

$32 Million

Has Completed a Growth Equity Financing

Has Completed an Oversubscribed Growth Equity Round

Received an equity investment from

Has sold its business to

Received an equity investment from

Has sold its business to

Has been acquired by

Has been acquired by an Undisclosed Family Office

Capital Raise

Has sold its business to

Has Sold its Energy Management Business to

Has Acquired

$120 Million

Has Received an Investment From

Has Acquired

Has Purchased

Acquisition Funding Provided By

Has Sold Its Business To

Has Sold Its Smart Grid Solutions Business To

Has Issued 5,000,000 Shares of Series A Preferred Stock

Has Sold Its Business To

$15,000,000

View More Transactions

News November 08, 2023

Outcome Capital Announces Electronic Registry Systems (ERS) Acquisition by Health Catalyst

Boston – November 8, 2023 Outcome Capital, a specialized life science advisory and investment banking firm, today announced that Electronic Registry Systems, Inc. (ERS), a leading provider of cancer registry solutions and compliance and informatics services, has been acquired by Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a healthcare technology and data analytics company with […]

Outcome Capital Life Sciences Pulse, October 2023

Outcome Capital Life Science Market Pulse October 2023 Click to view our LifeSciences Pulse Newsletter

Download

Contact Us for More Information

Would you like to learn more about working with Outcome Capital or discuss your specific needs?

Life Sciences

Healthcare

View Our Monthly Newsletter

Unique Insights

In-Depth Industry Experience & Networks

Personal Commitment to Clients

Exceptional Record of Success

Community

Outcome Capital as one of the Top 10 Life Science Financial Service Providers 2023

Driven to create value for our clients to secure the best possible outcome

John D Green, MD CEO, Advanced Uro-Solutions

Ray Apy CEO, Annese & Associates

The diversity of backgrounds enables Outcome to offer deep understanding and unique insights

Victor Esch, PhD President & CEO, DNAe

Rolf Purzer CEO, ATPCO

A true partner and collaborator

Rohit Nayak CEO, Electronic Registry Systems

In-depth industry knowledge & networks

Johan Pontin CEO, Beryllium Discovery

Mahfuz Ahmed CEO, DISYS

Passionately working for our clients' success

Lisa Dunlea CEO, XableCath

Andrew Ferrara Chairman, Boston Healthcare Associates

Sami El-Saden Chairman and CEO, Verrix

William Peterson Founder & Director, Propella Therapeutics

News November 08, 2023

Outcome Capital Announces Electronic Registry Systems (ERS) Acquisition by Health Catalyst

Resources October 2023

Outcome Capital Life Sciences Pulse, October 2023